{"analyses":[{"ciLowerLimit":"0.94","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.47","estimateComment":"An odds ratio \\> 1 favours osimertinib.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.069","paramType":"Odds Ratio (OR)","paramValue":"2.06","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.5","upperLimit":"93.5","value":"88.8"},{"groupId":"OG001","lowerLimit":"68.4","upperLimit":"88.0","value":"79.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Percentage of patients who have a best overall response of complete response (CR), partial response (PR) or stable disease (SD) as assessed by BICR","dispersionType":"95% Confidence Interval","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months","title":"Disease Control Rate by Blinded Independent Central Review (BICR)","type":"SECONDARY","unitOfMeasure":"% of participants"}